Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Bruton Tyrosine Kinase Inhibitor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT05640102
What this trial is testing

Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia

Who this might be right for
Waldenstrom Macroglobulinemia
BeiGene 111
Early research (Phase 1)Study completedNCT02112526
What this trial is testing

Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

Who this might be right for
Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)
Acerta Pharma BV 21
Large-scale testing (Phase 3)Active Not RecruitingNCT06840392
What this trial is testing

Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa

Who this might be right for
Hidradenitis Suppurativa
Novartis Pharmaceuticals 565
Early research (Phase 1)Study completedNCT02829541
What this trial is testing

A Phase 1, Single-Ascending-Dose, Safety, Tolerability, Pharmacokinetic(PK), and Pharmacodynamic(PD) Study of BIIB068 in Healthy Participants

Who this might be right for
Systemic Lupos Erythematosus, SLE
Biogen 36
Testing effectiveness (Phase 2)Study completedNCT01109069
What this trial is testing

Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia

Who this might be right for
B-cell Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaDiffuse Well-differentiated Lymphocytic Lymphoma+7 more
Pharmacyclics LLC. 199
Large-scale testing (Phase 3)Active Not RecruitingNCT04170283
What this trial is testing

Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib

Who this might be right for
B-cell Malignancies
BeOne Medicines 955
Large-scale testing (Phase 3)Study completedNCT05032157
What this trial is testing

Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines

Who this might be right for
Chronic Spontaneous Urticaria
Novartis Pharmaceuticals 455
Large-scale testing (Phase 3)Active Not RecruitingNCT06799000
What this trial is testing

Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

Who this might be right for
Hidradenitis Suppurativa
Novartis Pharmaceuticals 588
Large-scale testing (Phase 3)Not Yet RecruitingNCT07766421
What this trial is testing

Evaluation of Iopofosine I 131 vs. R-CD in WM Patients

Who this might be right for
Waldenstrom MacroglobulinaemiaWaldenstrom MacroglobulinemiaWaldenstrom's Macroglobulinaemia Refractory+2 more
Cellectar Biosciences, Inc. 219
Early research (Phase 1)Active Not RecruitingNCT02717624
What this trial is testing

Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL

Who this might be right for
Mantle Cell Lymphoma (MCL)
Acerta Pharma BV 72
Not applicableApproved For MarketingNCT05172700
What this trial is testing

Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer

Who this might be right for
Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Lymphocytic, SmallLymphoma, Mantle-Cell+2 more
Loxo Oncology, Inc.
Testing effectiveness (Phase 2)UnknownNCT02689869
What this trial is testing

Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma

Who this might be right for
Indolent Non-Hodgkin Lymphoma
Ludwig-Maximilians - University of Munich 98
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07508995
What this trial is testing

Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)

Who this might be right for
Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center 40
Large-scale testing (Phase 3)Active Not RecruitingNCT04666038
What this trial is testing

Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Who this might be right for
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Loxo Oncology, Inc. 238
Testing effectiveness (Phase 2)Study completedNCT03889639
What this trial is testing

Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis

Who this might be right for
Relapsing Multiple Sclerosis
Sanofi 130
Testing effectiveness (Phase 2)Looking for participantsNCT07221500
What this trial is testing

NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Who this might be right for
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
Nurix Therapeutics, Inc. 100
Testing effectiveness (Phase 2)Study completedNCT02315326
What this trial is testing

Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Who this might be right for
Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL)Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
Memorial Sloan Kettering Cancer Center 93
Large-scale testing (Phase 3)WithdrawnNCT02735876
What this trial is testing

Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Who this might be right for
Mantle Cell Lymphoma
Acerta Pharma BV
Large-scale testing (Phase 3)Study completedNCT01611090
What this trial is testing

Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Who this might be right for
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Janssen Research & Development, LLC 578
Large-scale testing (Phase 3)Looking for participantsNCT01804686
What this trial is testing

A Long-term Extension Study of PCI-32765 (Ibrutinib)

Who this might be right for
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaMantle Cell Lymphoma+4 more
Janssen Research & Development, LLC 700
Next Page